Expert opinion on biological therapy · 2012 · Review · PMID 22074294
Limitations: Related molecule only: full-length thymosin beta-4, not a TB-500 fragment trial.
Explore the library
Preclinical evidenceThymosin-beta-4-related fragment label
TB-500
TB-500 is a label used for thymosin-beta-4-related research peptides, including the LKKTETQ fragment identified by FDA. It should not be assumed to mean full-length thymosin beta-4.
Also indexed as: Thymosin Beta-4 fragment
A clear starting point
TB-500 is a label used for thymosin-beta-4-related research peptides, including the LKKTETQ fragment identified by FDA. It should not be assumed to mean full-length thymosin beta-4.
Systems mapping shows biological relevance, not a treatment recommendation or a patient CPI score.
No validated chemical structure is displayed in this edition.
How it works
Actin / cell migration
TB-500 is a label used for thymosin-beta-4-related research peptides, including the LKKTETQ fragment identified by FDA. It should not be assumed to mean full-length thymosin beta-4.
- Targets & processes
- Actin / cell migration
- Systems & tissues
- See the pathway description; category links describe research relevance, not demonstrated treatment effects.
What does the evidence show?
Cell migration and tissue-repair hypotheses.
What this does not establish
The cited review concerns full-length thymosin beta-4. Its human research cannot be transferred to the TB-500 fragment; direct fragment evidence is limited.
Citation metadata from PubMed, a service of the U.S. National Library of Medicine, NIH. A citation match is not a guarantee of study quality. Abstracts are not full-text reviews.
Safety is a separate question
FDA identifies no human exposure data for the nominated LKKTETQ fragment and notes immunogenicity and impurity concerns. TB-500 names may refer to differing products.
Contraindications & cautions
Not an exhaustive contraindication review. FDA identifies no human exposure data for the nominated LKKTETQ fragment and notes immunogenicity and impurity concerns. TB-500 names may refer to differing products.
Medication & supplement interactions
Interaction information is incomplete. FDA identifies no human exposure data for the nominated LKKTETQ fragment and notes immunogenicity and impurity concerns. TB-500 names may refer to differing products.
Regulatory status · United States
Not FDA-approved. No FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval.
Read the official sourceThis is not an exhaustive safety list. Regulatory status varies by jurisdiction and product; investigational use is not approval.
Make the science interactive
A dedicated lesson has not been published for this ingredient yet. Explore the cited profile or ask the instructor.
Your scientific classroom
Ask the IW Science Instructor
Basic level · Published sources only · AI evidence check
Ask about general science. Do not enter names, personal health details or medication lists. This is not a clinical consultation. Discussion stays in this browser’s private learning session for up to 90 days.
All medications and therapies discussed are for educational purposes only. Prescriptions are determined independently by the licensed clinician following a medical evaluation. There is no guarantee that any medication or peptide will be prescribed.
IW Interactive Learning Engine · Adapted from stable OpenMAIC v1.2.1. Open-source license
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.